rxevidence.com

Seasonal influenza vaccines (2026–2027 season)

Vaccine Academy › Vaccine School › Routine adult

Vaccine School · Routine adult

A pharmacist-focused lesson on seasonal influenza vaccination: the vaccine types and products, who should receive which product by age and risk, dosing and timing, administration, storage, contraindications, safety, special populations and counseling, with CDC's interim 2026–2027 considerations side by side with FDA labeling. Unreviewed draft.

Content current as of October 11, 2026. AI-assisted draft; not yet reviewed by a licensed pharmacist. Current CDC schedules: immunization schedules.

The disease and why it matters

Influenza is a contagious disease that spreads around the United States every year, usually between October and May. Anyone can get it, but infants and young children, people 65 years and older, pregnant women, and people with certain health conditions or a weakened immune system are at greatest risk of complications such as pneumonia, bronchitis, sinus infections and ear infections. [1]

In an average year thousands of people in the United States die from flu and many more are hospitalized; flu vaccine prevents millions of illnesses and flu-related doctor visits each year. [1]

CDC's interim 2026–2027 considerations list populations at higher risk for medical complications from severe influenza: all children aged 6 through 59 months, all persons aged 50 years and older, people with chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic or metabolic disorders (including diabetes mellitus), people who are immunocompromised, women who are or will be pregnant during the influenza season, children and adolescents on aspirin- or salicylate-containing medications, residents of nursing homes and other long-term care facilities, American Indian or Alaska Native persons, and persons who are extremely obese (BMI 40 or more for adults). [2]

Influenza vaccine does not cause flu; it takes about 2 weeks for protection to develop after vaccination, and each year a new vaccine is made to protect against the viruses believed likely to cause disease in the upcoming season. [1]

Video and figures

Video

The video loads from YouTube when played.

What is influenza?
Channel: World Health Organization (WHO) · Uploaded March 17, 2022 · Confirmed available October 12, 2026 · Open on YouTubeThis video is more than three years old; recommendations in it may be out of date.RxEvidence has not checked every statement in this video.

Get CE credit

  • CDC You Call the Shots: Influenza module, CDC TRAIN course WB4688 — CDC · Free (CDC states no fees for its CE activities) · accredited by CDC, jointly accredited by ACCME, ACPE and ANCC; pharmacy UAN JA4008229-0000-23-064-H06-P. CDC's listing shows credit expiring 9/4/2025, so confirm on CDC TRAIN that credit is still available and current · link confirmed October 11, 2026

RxEvidence is not an accredited continuing education provider and does not award CE credit. These are links to activities offered by others.

Products available

Three types of influenza vaccines are licensed and currently available in the United States: inactivated influenza vaccines (IIV3), recombinant influenza vaccine (RIV3) and live attenuated influenza vaccine (LAIV3). The seasonal vaccines available are trivalent, containing an influenza A(H1N1)pdm09 virus, an influenza A(H3N2) virus and an influenza B/Victoria virus, and the composition is determined annually by FDA. [2]

Influenza vaccines in CDC's 2026–2027 interim Table 1, with FDA product page and label details
VaccineTypeManufacturer (FDA page)Age indication (CDC Table 1 / FDA label)Dose and route
FluarixStandard-dose egg-based IIV3 [2]GlaxoSmithKline Biologicals SA [3]6 months and older [4]0.5 mL intramuscular
FlulavalStandard-dose egg-based IIV3 [2]ID Biomedical Corporation of Quebec dba GlaxoSmithKline Biologicals [5]6 months and older [6]0.5 mL intramuscular
FluzoneStandard-dose egg-based IIV3 [2]Sanofi Vaccines US Inc. [7]6 months and older [8]0.5 mL intramuscular (6 through 35 months: 0.25 mL or 0.5 mL per the label; 0.25-mL syringes no longer available)
Fluzone High-DoseHigh-dose egg-based IIV3 (60 μg HA per 0.5 mL) [2]Sanofi Vaccines US Inc.65 years and older [2]0.5 mL intramuscular
FlucelvaxCell culture-based IIV3 [2]Seqirus Inc. [9]6 months and older [10]0.5 mL intramuscular
FluadMF59-adjuvanted egg-based IIV3 [2]Seqirus, Inc. [11]Adults 65 years and older; indication approved under accelerated approval based on immune response [12]0.5 mL intramuscular
FlublokRecombinant HA vaccine (RIV3), 45 μg HA per 0.5 mL [2]Protein Sciences Corporation [13]9 years and older [14]0.5 mL intramuscular
FluMistLive attenuated egg-based influenza vaccine (LAIV3), intranasal [2]MedImmune, LLC [15]2 through 49 years [16]0.2 mL intranasal (0.1 mL in each nostril)
AfluriaInactivated influenza vaccine; FDA-licensed but not listed in CDC's Table 1 (CDC notes the table does not list all licensed products) [17] [2]Seqirus Pty. Ltd.6 months and older [18]Intramuscular by needle and syringe (6 months and older); PharmaJet Stratis needle-free system for 18 through 64 years
MflusivamRNA influenza vaccine (Influenza Vaccine, mRNA), 2026–2027 formula [19]ModernaTX, Inc. [20]50 years and older; indication for 65 years and older approved under accelerated approval based on immune responses [19]Single 0.38 mL intramuscular dose [19]

MFLUSIVA was approved by FDA under accelerated approval effective August 5, 2026. CDC's interim 2026–2027 considerations page (September 1, 2026) lists IIV3, RIV3 and LAIV3 products and does not mention an mRNA influenza vaccine, so no CDC product-specific recommendation for MFLUSIVA appears on that page. [21] [2]

FluMist (LAIV3) is approved by FDA for self-administration (recipients aged 18 through 49 years) or administration by a caregiver aged 18 years or older (children and adolescents aged 2 through 17 years), through the FluMist Home program; recommendations, contraindications and precautions are the same as for health care provider administration. [2]

Who should get it

CDC (interim clinical considerations, 2026–2027 season)

As of September 1, 2026

CDC states that, because of legal uncertainties and inquiries, the recommendations for seasonal influenza vaccination from the July 2025 immunization schedule remain in effect for the 2026–2027 influenza season; routine annual influenza vaccination is recommended as described in that schedule, and all persons should receive an FDA-licensed age-appropriate influenza vaccine. [2]

AAFP (its adopted adult schedule; page checked 2026-10-11, no version date shown on the page)

As of October 11, 2026

Lists for adults 19 years or older 1 dose of any influenza vaccine appropriate for age and health status annually, and for age 65 years or older any one of HD-IIV3, RIV3 or aIIV3 as preferred. [22]

FDA labels (Fluarix, Flulaval, Fluzone, Flucelvax, Afluria)

As of October 11, 2026

Each is approved for persons 6 months of age and older; FDA labeling does not rank products by age group. [4] [6] [8] [10] [18]

CDC: January 2026 schedule revision and its legal status (influenza)

As of June 11, 2026

On January 5, 2026 the CDC Acting Director approved a revised childhood and adolescent schedule that changed the recommendation type for rotavirus and influenza vaccines from a full recommendation for all children to a shared clinical decision-making recommendation; the schedule's first category (recommended for all children) lists measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Hib, pneumococcal disease, HPV and varicella. A federal district court stayed that schedule on March 16, 2026 and reverted it to the version as of May 2025, and CDC's schedule page continues to show the July 2, 2025 addendum edition. [23] [24] [25]

American Academy of Pediatrics 2026 schedule (endorsed by AAFP, ACOG, AMA, IDSA, APhA and others)

As of January 26, 2026

The AAP published its own 2026 schedule on January 26, 2026, which continues to recommend routine immunization for protection against 18 diseases, including RSV, hepatitis A, hepatitis B, rotavirus, influenza and meningococcal disease, and differs from the schedule recently issued by CDC; the AAP schedule is formally endorsed by 12 organizations, including AAFP, ACOG, AMA, IDSA and the American Pharmacists Association. [26]

The 2025–26 ACIP report recommended routine annual influenza vaccination for all persons aged 6 months and older without a contraindication, and added a recommendation that children aged 18 years and younger, pregnant women and all adults receive seasonal influenza vaccines only in single-dose formulations free of thimerosal as a preservative. [27]

There are no preferential recommendations for any one influenza vaccine over another when more than one licensed and recommended vaccine is available, except for adults aged 65 years and older, for whom high-dose inactivated (HD-IIV3), recombinant (RIV3) or adjuvanted inactivated (aIIV3) vaccine is preferentially recommended; if none of the three is available, any other age-appropriate influenza vaccine should be given. [2]

Health care personnel, including pharmacists, and household contacts and caregivers of children aged 59 months and younger and of adults aged 50 years and older, are among the people CDC emphasizes vaccinating because they live with or care for people at higher risk. [2]

Dosing and schedule, including catch-up

Persons aged 9 years and older should receive 1 dose of the current season's trivalent influenza vaccine annually; revaccination (a booster dose) of persons who have been fully vaccinated for the season is not recommended, regardless of when the current season's vaccine was received. [2]

Some children aged 6 months through 8 years require 2 doses at least 4 weeks apart. Children who have previously received at least 2 total doses of trivalent or quadrivalent influenza vaccine at least 4 weeks apart before the July 1 immediately prior to the start of the season need 1 dose; those who have not, or whose history is unknown, need 2 doses, given as soon as possible (including in July and August if vaccine is available) so the second can be received, ideally, by the end of October. A child aged 8 years who needs 2 doses should receive both even if the child turns 9 between doses. [2]

Timing: for most persons who need only 1 dose, vaccination should ideally be offered during September or October. Vaccination during July and August is not recommended for most groups because of potential waning of immunity over the season, particularly among older adults, but can be considered for anyone for whom later vaccination may not be possible, and for pregnant women in the third trimester. Vaccination should continue after October and throughout the season as long as influenza viruses are circulating and unexpired vaccine is available. [2]

The approved dose volume for IIV3s and RIV3 is 0.5 mL intramuscularly, with one exception: Fluzone for children 6 through 35 months may be given at either 0.25 mL or 0.5 mL per dose (0.25-mL syringes are no longer available); FluMist is 0.2 mL intranasally (0.1 mL in each nostril). [2]

Administration

IIV3s and RIV3 are administered intramuscularly by needle and syringe; for older children and adults the recommended site is the deltoid muscle, and for infants and young children the preferred site is the anterolateral thigh. LAIV3 is administered intranasally. [2]

IIV3s and RIV3 can be given simultaneously or sequentially with other inactivated or live vaccines, at separate anatomic sites; vaccines more likely to cause local injection-site reactions (e.g., HD-IIV3 and aIIV3) should be given in different limbs, if possible. LAIV3 can be given simultaneously with other live or inactivated vaccines, but if two live vaccines are not given simultaneously at least 4 weeks should pass before another live vaccine. [2]

Influenza antivirals: administration of any IIV3 or RIV3 to persons receiving antivirals is acceptable. Oseltamivir and zanamivir might interfere with LAIV3 if given from 48 hours before through 2 weeks after vaccination, peramivir from 5 days before through 2 weeks after, and baloxavir from 17 days before through 2 weeks after; people who receive antivirals within those intervals should be revaccinated with an age-appropriate IIV3 or RIV3. [2]

Travelers: those who want to reduce their risk should consider vaccination, preferably at least 2 weeks before departure; influenza vaccine formulated for the Southern Hemisphere might differ in composition and most Southern Hemisphere formulations are not licensed in the United States. [2]

Storage and handling

CDC advises that influenza vaccines should typically be protected from light and stored at the temperature recommended in the package insert, usually 36°F to 46°F (2°C to 8°C), maintained at all times with adequate refrigeration and temperature monitoring; vaccine that has frozen should be discarded, and vaccines should not be used beyond the expiration date. Multidose vials may also have a beyond-use date, and no more than the specified number of doses should be removed. [2]

Storage statements in the prescribing information
VaccineLabel statement
FluarixStore refrigerated between 2º and 8ºC (36º and 46ºF). [4]
FlulavalStore refrigerated between 2º and 8ºC (36º and 46ºF). [6]
FluzoneStore all Fluzone presentations refrigerated at 2° to 8°C (35° to 46°F). [8]
FlucelvaxStore this product refrigerated at 2°C to 8°C (36ºF to 46ºF). [10]
FluadStore FLUAD refrigerated at 2°C to 8°C (36°F to 46°F). [12]
FlublokStore refrigerated between 2° and 8°C (36° and 46°F). [14]
FluMistStore in a refrigerator between 35°F to 46°F (2°C to 8°C) in its carton to protect from light; may be kept at room temperature (68°F to 77°F) in its carton for a maximum of 12 hours; do not freeze. [16]
AfluriaStore refrigerated at 2−8°C (36−46°F). [18]
MflusivaStore refrigerated between 2°C to 8°C (36°F to 46°F). [19]

Contraindications and precautions

  • Each influenza vaccine is contraindicated for persons with a history of previous severe allergic reaction (e.g., anaphylaxis) to any component of that vaccine, other than egg protein. [2]
  • Egg allergy: persons aged 6 months and older with egg allergy may receive any influenza vaccine (egg-based or non-egg-based) that is otherwise appropriate for age and health status, and egg allergy alone necessitates no additional safety measures beyond those recommended for any vaccine recipient. [2]
  • Precaution: a history of Guillain-Barré syndrome (GBS) within 6 weeks of a previous dose of any type of influenza vaccine; people not at higher risk of complications who had GBS within 6 weeks of a previous influenza vaccination typically should not be vaccinated, but the benefits might outweigh the risks for some who are at higher risk. [2]
  • Precaution: moderate or severe acute illness with or without fever is a general precaution for vaccination. [2]
  • LAIV3 (FluMist) contraindications include: severe allergic reaction to any component or to a previous dose of any influenza vaccine; children and adolescents receiving aspirin- or salicylate-containing medications; children aged 2 through 4 years with asthma or recurrent wheezing in the previous 12 months; children and adults who are immunocompromised; close contacts and caregivers of severely immunosuppressed persons who require a protected environment; pregnancy; active communication between the CSF and the oropharynx, nasopharynx, nose or ear or any other cranial CSF leak; cochlear implants; and receipt of influenza antiviral medication within the previous 48 hours (oseltamivir, zanamivir), 5 days (peramivir) or 17 days (baloxavir). [2]
  • Precautions for LAIV3 also include asthma in persons aged 5 years and older and other underlying medical conditions that might predispose to complications after wild-type influenza virus infection. [2]
  • Mflusiva: contraindicated with a history of severe allergic reaction (e.g., anaphylaxis) to Mflusiva or any of its components; if GBS has occurred within 6 weeks following previous influenza vaccination, the decision to give it should be based on careful consideration of potential benefits and risks. [19]

Safety and adverse events

CDC's VIS lists soreness, redness and swelling where the shot is given, fever, muscle aches and headache as possible after influenza vaccination, and says there may be a very small increased risk of Guillain-Barré syndrome after inactivated influenza vaccine. [1]

Young children who get the flu shot along with pneumococcal conjugate vaccine and/or DTaP vaccine at the same time might be slightly more likely to have a seizure caused by fever. [1]

Mflusiva's most commonly reported (10% or more) adverse reactions in participants 50 through 64 years were injection site pain 68.7%, fatigue 48.1%, headache 41.9%, myalgia 40.6%, arthralgia 31.5%, chills 27.5% and axillary swelling or tenderness 20.3%; in participants 65 years and older they were injection site pain 62.9%, fatigue 42.1%, headache 33.7%, myalgia 30.2%, arthralgia 24.1%, chills 18.1% and axillary swelling or tenderness 14.2%. [19]

Syncope can occur after injectable vaccines; people sometimes faint after medical procedures including vaccination. [1]

Special populations

Pregnancy: pregnant women should receive IIV3 or RIV3; LAIV3 should not be used during pregnancy but can be used postpartum; influenza vaccine can be given at any time during pregnancy, and early vaccination (July and August) can be considered for women in the third trimester because it can protect the infant during the first months of life. [2]

Immunocompromised persons should receive an age-appropriate IIV3 or RIV3, with the exception that solid organ transplant recipients aged 18 through 64 years receiving immunosuppressive regimens may receive either HD-IIV3 or aIIV3 as acceptable options (without a preference over other age-appropriate IIV3s or RIV3); LAIV3 should not be used. [2]

Older adults: adults 65 years and older should preferentially receive HD-IIV3, RIV3 or aIIV3. Of these, Fluzone High-Dose is approved for 65 years and older, Fluad for 65 years and older (accelerated approval), and Flublok for 9 years and older. [2] [12] [14]

People who live with or care for severely immunocompromised persons who require a protected environment should not receive LAIV3; if LAIV3 is given, they should avoid contact with or caring for such persons for 7 days after vaccination, but need not be restricted from caring for or visiting less severely immunocompromised persons. [2] [22]

Counseling pearls for the pharmacy counter

  • Influenza vaccine does not cause flu, and it takes about 2 weeks for protection to develop. [1]
  • Even when the vaccine does not exactly match circulating viruses, it may still provide some protection. [1]
  • Tell the vaccination provider about an allergic reaction after a previous dose of influenza vaccine or any severe, life-threatening allergy, and about any history of Guillain-Barré syndrome. [1]
  • For the nasal spray, tell the provider if the person is pregnant, has a weakened immune system, has asthma, has taken influenza antiviral medication in the last 3 weeks, or cares for severely immunocompromised people who require a protected environment. [28]
  • Everyone 6 months and older should be vaccinated every flu season; children 6 months through 8 years may need 2 doses in a season, and everyone else needs only 1 dose each season. [1]

Common patient questions

Which flu vaccine should a 70-year-old receive?

CDC preferentially recommends high-dose inactivated influenza vaccine (Fluzone High-Dose), recombinant influenza vaccine (Flublok) or adjuvanted inactivated influenza vaccine (Fluad); if none is available, any other age-appropriate vaccine should be given. [2]

My patient has a severe egg allergy. Can they get a flu shot?

Yes. CDC says persons aged 6 months and older with egg allergy may receive any influenza vaccine that is otherwise appropriate for age and health status, and egg allergy alone needs no additional safety measures. [2]

A patient had a flu shot in August. Do they need another in October?

No. CDC says revaccination (a booster dose) of persons fully vaccinated for the season is not recommended, regardless of when the season's vaccine was received. [2]

Can a pregnant patient receive FluMist?

No. LAIV3 should not be used during pregnancy but can be used postpartum; pregnant women should receive IIV3 or RIV3. [2]

A 6-year-old got one dose last season and none before. How many doses now?

Two doses at least 4 weeks apart, because the child has not previously received at least 2 doses before the July 1 prior to the season. [2]

References

  1. Centers for Disease Control and Prevention. Influenza (flu) vaccine (inactivated or recombinant): what you need to know. Vaccine Information Statement, January 31, 2025. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/current-vis/influenza-inactivated.html. Accessed October 11, 2026.
  2. Centers for Disease Control and Prevention. Interim clinical considerations for the use of seasonal influenza vaccines in the United States. Page dated September 1, 2026. Accessed October 11, 2026. https://www.cdc.gov/flu/hcp/vax-summary/seasonal-influenza-vaccines.html. Accessed October 11, 2026.
  3. U.S. Food and Drug Administration. FLUARIX product page (content current as of 07/02/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/fluarix. Accessed October 11, 2026.
  4. FLUARIX (influenza vaccine) injectable suspension, for intramuscular use: prescribing information. GlaxoSmithKline Biologicals; revised 7/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/84804/download?attachment. Accessed October 11, 2026.
  5. U.S. Food and Drug Administration. FLULAVAL product page (content current as of 07/16/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/flulaval. Accessed October 11, 2026.
  6. FLULAVAL (influenza vaccine) injectable suspension, for intramuscular use: prescribing information. ID Biomedical Corporation of Quebec; revised 7/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/191667/download?attachment. Accessed October 11, 2026.
  7. U.S. Food and Drug Administration. Fluzone, Fluzone High-Dose product page (content current as of 07/02/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/fluzone-and-fluzone-high-dose. Accessed October 11, 2026.
  8. Fluzone, Fluzone High-Dose (influenza vaccine) injectable suspension, for intramuscular use: prescribing information. Sanofi Pasteur; revised 7/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/170019/download?attachment. Accessed October 11, 2026.
  9. U.S. Food and Drug Administration. FLUCELVAX product page (content current as of 07/02/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/flucelvax. Accessed October 11, 2026.
  10. FLUCELVAX (influenza vaccine) injectable suspension, for intramuscular use: prescribing information. Seqirus; revised 7/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/85322/download. Accessed October 11, 2026.
  11. U.S. Food and Drug Administration. FLUAD product page (content current as of 07/02/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/fluad. Accessed October 11, 2026.
  12. FLUAD (influenza vaccine, adjuvanted) injectable suspension, for intramuscular use: prescribing information. Seqirus; revised 6/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/179766/download?attachment. Accessed October 11, 2026.
  13. U.S. Food and Drug Administration. FLUBLOK product page (content current as of 07/02/2025). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/flublok. Accessed October 11, 2026.
  14. FLUBLOK (influenza vaccine) injection, for intramuscular use: prescribing information. Sanofi Pasteur (Protein Sciences Corporation); revised 7/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/179778/download?attachment. Accessed October 11, 2026.
  15. U.S. Food and Drug Administration. FLUMIST product page (content current as of 11/28/2025). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist. Accessed October 11, 2026.
  16. FLUMIST (influenza vaccine live, intranasal): prescribing information. MedImmune, LLC; revised 07/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/180697/download?attachment. Accessed October 11, 2026.
  17. U.S. Food and Drug Administration. AFLURIA, AFLURIA Southern Hemisphere product page (content current as of 03/25/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/afluria-afluria-southern-hemisphere. Accessed October 11, 2026.
  18. AFLURIA (influenza vaccine) injectable suspension: prescribing information. Seqirus Pty. Ltd.; revised 03/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/81559/download?attachment. Accessed October 11, 2026.
  19. MFLUSIVA (influenza vaccine, mRNA) injectable suspension, for intramuscular use, 2026-2027 formula: prescribing information. ModernaTX, Inc.; revised 8/2026. U.S. Food and Drug Administration. Accessed October 11, 2026. https://www.fda.gov/media/194120/download?attachment. Accessed October 11, 2026.
  20. U.S. Food and Drug Administration. MFLUSIVA product page (content current as of 09/02/2026). Accessed October 11, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva. Accessed October 11, 2026.
  21. U.S. Food and Drug Administration. BLA approval and accelerated approval letter, Influenza Vaccine, mRNA (MFLUSIVA), STN BL 125869/0. August 5, 2026. Accessed October 11, 2026. https://www.fda.gov/media/194121/download?attachment. Accessed October 11, 2026.
  22. American Academy of Family Physicians. Adults 19 and older immunization schedules (adopted version; page shows no version date). Accessed October 11, 2026. https://www.aafp.org/clinical-insights/immunizations-and-vaccines/immunizations-schedules-resources/adult-immunization-schedules. Accessed October 11, 2026.
  23. Congressional Research Service. The 2026 Childhood Immunization Schedule (R48982). June 11, 2026. Accessed October 11, 2026. https://www.congress.gov/crs_external_products/R/PDF/R48982/R48982.1.pdf. Accessed October 11, 2026.
  24. Centers for Disease Control and Prevention. CDC acts on Presidential Memorandum to update childhood immunization schedule. News release, January 5, 2026. Accessed October 11, 2026. https://www.cdc.gov/media/releases/2026/2026-cdc-acts-on-presidential-memorandum-to-update-childhood-immunization-schedule.html. Accessed October 11, 2026.
  25. Centers for Disease Control and Prevention. Healthcare professionals: immunization schedules. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html. Accessed October 11, 2026.
  26. American Academy of Pediatrics. AAP releases recommended childhood and adolescent immunization schedule for 2026. HealthyChildren.org news. Accessed October 11, 2026. https://healthychildren.org/English/news/Pages/AAPs-recommended-childhood-and-adolescent-immunization-schedule-for-2026.aspx. Accessed October 11, 2026.
  27. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2025–26 influenza season. MMWR Morb Mortal Wkly Rep. 2025;74(32):500-507. Accessed October 11, 2026. https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a2.htm. Accessed October 11, 2026.
  28. Centers for Disease Control and Prevention. Influenza (flu) vaccine (live, intranasal): what you need to know. Vaccine Information Statement, January 31, 2025. Accessed October 11, 2026. https://www.cdc.gov/vaccines/hcp/current-vis/influenza-live-intranasal.html. Accessed October 11, 2026.

For professional education. Check current labeling and guidance before acting. Not medical advice.

Scroll to Top